Vertebral Augmentation Using VCFix Spinal System in Stand-alone Configuration

NCT07259811 | Active Not Recruiting

• 1 other identifier: CIP-VS01-EU
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 2

Brief Summary

This study will review the safety and possibility of the VCFix Spinal System. This is a proof-of-concept study and an initial review of the surgical procedure and how well the VCFix device works, to who that the VCFix is safe and works well in early testings, so that a larger safety study can be done later to help get CE approval. The VCFix Spinal System will be used in its independent setup, within its planned use for treatment of vertebral compression fracture. It's designed to be a small early study to test safety and see if the treatment idea is possible, with one group and no blinding. Two hospitals in EU will enroll in total 10 participants with a single vertebral fracture that will undergo the same surgery. The main test goals are: how successful the access creation of the vertebral body is using the VCFix Preparation kit according to the provided instructions, how successful the positioning of the VCFix implant is by using the VCFix Implantation kit according to the provided instructions, and how successful the fracture reduction by expanding the VCFix implant according to the provided instructions. The main safety goal is: number of device-/procedure-related major side effects through 30 days after the initial procedure. Participant enrollment will last around 12 months. Each participant will be followed for 2 years after the implantations. All side effects related to the spine will be documented throughout the study.

Conditions

Vertebral Compression Fracture

Keywords

VCF; FIH; vertebral stabilization; fracture; trauma; osteoporosis; expandable implant

Outcome Measures

Primary Outcomes (4)

• Outcome measure

  Rate of successful vertebral body access creation through use of the VCFix Preparation kit according to the provided labelling

  2 years

• Outcome measure

  Rate of successful positioning of the VCFix implant through use of the VCFix Implantation kit according to the provided labelling

  2 years

• Outcome measure

  Rate of successful fracture reduction by expansion of the VCFix implant according to the provided labelling

  2 years

• Outcome measure

  Number of device-/procedure-related serious adverse events

  30 days after index procedure

Study Arms (1)

VCFix Spinal System

EXPERIMENTAL

Device: VCFix Spinal System in stand-alone configuration

Interventions

VCFix Spinal System in stand-alone configuration DEVICE

The distinguishing features of this intervention reside in: 1. In situ adjustment and maintenance of the height and angle of the device that allows expansion of the fractured VB in the cranio-caudal direction to realign the vertebral endplates and correct kyphosis. 2. The complex titanium perforated structure with optimized surface roughness that allows possible bone attachment, thereby permitting natural healing of the bone and potentially providing more stability to the device and the treated vertebra over time. 3. The ability to likely secure and reinforce the vertebra without using PMMA bone cement, avoiding all the symptomatic and asymptomatic side effects of bone cement. 4. The ability to connect the posterior to the anterior column of the spine through the pedicle screw component of the VCFix implant, therefore improving the biomechanical load distribution and consequently the ability to stabilize more severe fractures.

VCFix Spinal System

Eligibility Criteria

• Age: 22 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or Female between 22 and 85 years of age
• One (single) vertebral fracture which meets all the following criteria:
• Type A fractures as defined by the AO spine classification (compression injuries)1
• Vertebral fracture located in the thoracic and lumbar regions of the spine
• Fracture age \<6 weeks or fractures with anatomic signs of reducibility (based on radiographic evidence as well as patient history)
• Vertebral fracture shows an estimated height loss in the anterior or mid third of the vertebral body (VB) of at least 10% but not more than 70% based on radiographic evidence
• Target VB has appropriate anatomy, i.e., suitable pedicle diameter, pedicle length and chord length that would allow for selection of correct implant size, as described in the IFU and based on axial MRI/CT scan before surgery Patient has a Numerical Pain Rating Scale (NPRS) back pain score of ≥5
• Patient has an Oswestry Disability Index (ODI) score of ≥30/100
• Patient has a BMI \<35
• Patient is mentally capable of complying with trial protocol requirements for the duration of the study
• Patient can understand the risks and benefits of participating in the study and can provide written informed consent
• Patient is available for all study visits

You may not qualify if:

• Neoplasms with posterior involvement and/or presence of a mass within the spinal canal
• Non-mobile fractures (i.e., fracture is not recent (\>6 weeks), bone marrow oedema or fluid or empty cleft are not visible in radiographic imaging, or fracture mode does not allow for fracture reduction in craniocaudal direction) 2
• Vertebral fracture prior to the incident fracture
• Fracture to the pedicle based on radiographic evaluation
• Asymptomatic vertebral fractures
• Patient clearly improving with pharmacological treatment
• Previous spine surgery, balloon kyphoplasty or vertebroplasty, for any vertebral fracture
• Spinal cord compression or canal compromise requiring decompression
• Severe back pain due to causes other than acute fracture with NPRS score \> 5
• Pain due to any other condition that requires daily narcotic medication
• Pre-existing neurological deficit, radiculopathy or myelopathy
• Significant clinical comorbidity that the enrolling physician considers may either contraindicate surgery or interfere with long-term data collection or follow-up
• Pre-existing conditions such as:
• Allergy to any components of the device/instruments used during the procedure or to PMMA bone cement
• Active or incompletely treated infection of the vertebral column or active systemic infection, including unresolved urinary tract infection

Sponsors & Collaborators

• Amber Implants B.V.: lead
• Avania B.V.: collaborator

Study Sites (2)

Wilhelmsburger Krankenhaus Groβ-Sand

Hamburg, 21107, Germany

Location

Krankenhaus Mechernich

Mechernich, 53894, Germany

Location

MeSH Terms

Conditions

Fractures, Bone; Wounds and Injuries; Osteoporosis

Condition Hierarchy (Ancestors)

Bone Diseases, Metabolic; Bone Diseases; Musculoskeletal Diseases; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 21, 2025
• First Posted: December 2, 2025
• Study Start: September 18, 2023
• Primary Completion (Estimated): May 14, 2026
• Study Completion (Estimated): May 14, 2026
• Last Updated: December 2, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

DE (2)